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imited information exists on the incidence of symptom-
atic venous thromboembolism (VTE) in patients under-
going chest surgery for lung cancer. Several factors
increase the thromboembolic risk in patients undergoing
surgery for lung cancer: the intrinsic procoagulant effect of cancer,
extensive surgical intervention, dependent limb position in the oper-
ating room, and vessel injury consequent to the operation. Further-
more, these patients might be especially vulnerable to pulmonary
embolism (PE) because of the loss of lung tissue and the presence
of chronic obstructive pulmonary disease and cardiovascular dis-
eases caused by smoking.1
Older studies found a very high incidence of thromboembolic
events in these patients.2,3
However, the risk of thromboembolic complications in lung can-
cer surgery might have changed over the last years. Extensive use of
antithrombotic prophylaxis, improvement in surgical techniques
and perioperative care, and more prompt mobilization might have
reduced the risk of VTE.
Therefore, the aim of our study was to provide up-to-date reliable
data on the incidence of venous thromboembolic complication in
a large cohort of patients undergoing chest surgery for malignant
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Clinical Summary
We performed a chart review of all patients undergoing chest sur-
gery for malignant lung disease who were operated on between Jan-
uary 1, 2002, and December 1, 2004, at St Joseph’s Hospital,
Hamilton, Ontario, Canada, and between January 1, 2005, and
December 1, 2006, at 2 university hospitals in Italy (Varese and
Palermo). The charts of eligible patients were reviewed for baseline
clinical characteristics, including sex, age, prior history of cardio-
vascular disease, and use and type of antithrombotic prophylaxis.
Perioperative mortality and all objectively confirmed venous throm-
boembolic events were noted. Notes of follow-up ambulatory surgi-
cal visits were also reviewed within 4 weeks of hospital discharge
after surgical intervention to ensure that cases of VTE occurring
after discharge were not missed. The study protocol was approved
by the regional institutional review boards.
Baseline characteristics are summarized in Table 1. Six hundred
ninety-three patients were identified (mean age, 66.7 years; range,
23–90 years); 418 (60.6%) patients were male, and the median
length of hospitalization was 7 days. One hundred fifty-five
(22.5%) patients had a history of cardiovascular disease. Almost
90% of patients attended at least 1 follow-up ambulatory surgical
visit after discharge. Postoperative antithrombotic prophylaxis
with unfractionated heparin at a dose of 5000 U twice daily was
used in 464 (67.2%) patients, and low-molecular-weight heparin
was used in 153 (22.2%) patients. Only 16 (2.3%) patients did not
receive antithrombotic prophylaxis. Five hundred seven (73.5%) pa-
tients had primary lung cancer, and 183 had secondary malignant
lung cancer. Lung primary adenocarcinoma, epidermoid carcinoma,
and anaplastic cancer were the most common cancer histologies.
Ninety-three (13.5%) patients underwent pneumectomy, and 597
(86.5%) underwent lobectomy or wedge resection.
There were 12 (1.7%) venous thromboembolic complications, of
which 9 (1.3%) were PEs. All these complications occurred while
patients were receiving antithrombotic prophylaxis with unfractio-
nated or low-molecular-weight heparin. Twenty-one (3.0%) patients
died during hospitalization. However, mortality could be attributedracic and Cardiovascular Surgery c Volume 135, Number 3 705
Brief Communicationsto PE only in 4 (0.6%) patients, and other causes included septice-
mia and acute myocardial infarction.
Discussion
In our chart review we collected data on almost 700 patients under-
going chest surgery for malignant lung disease, and almost 90% of
these patients attended at least 1 follow-up visit. Venous thrombo-
embolic events within 1 month after surgical intervention were
uncommon in these patients. Incidence of VTE was lower than pre-
TABLE 1. Baseline characteristics
Total patient no. 690
Age, y (range) 66.7 (23–90)
Male sex, n (%) 418 (60.6)
History of cardiovascular
disease
155 (22.5%)
Antithrombotic prophylaxis,
n (%)
Postoperative UFH, 464 (67.2)
Postoperative LMWH, 153 (22.2)
Preoperative LMWH or UFH, 52 (7.5)
Bridging therapy, 5 (0.7)
No prophylaxis, 16 (2.3)
Type of cancer, n (%) Primary lung cancer, 507 (73.5)
Adenocarcinoma, 51.8%
Epidermoid, 28.6%
Anaplastic, 8.0%
Other, 11.6%
Secondary lung cancer, 183 (26.5)
Type of operation, n (%) Pneumectomy, 93 (13.5)
Lobectomy or wedge resection,
597 (86.5)
UFH, Unfractionated heparin; LMWH, low-molecular-weight heparin.Closure of a large tracheoesophagea
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racheoesophageal fistula (TEF) is an uncommon but dev-
astating complication of prolonged intubation. Pressure
exerted from the cuff of an endotracheal tube against
a rigid nasogastric tube causes tissue necrosis and break-
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706 The Journal of Thoracic and Cardiovascular Surgery c Maviously reported. In a previous study on 77 patients undergoing pul-
monary resection,2 20 (26%) had a venous thromboembolic event
(15 deep vein thromboses and 5 PEs) during hospitalization, and
in a retrospective study on 1735 patients who underwent lung resec-
tion,3 PE was a common fatal postoperative complication, account-
ing for 15.2% of postresectional deaths. However, because these
studies were carried out between 1975 and 1993, antithrombotic
prophylaxis with heparin was rarely used in these patients.
Finally, in a small recent study carried out in 50 patients under-
going lung surgery for cancer,4 PE was detected by means of multi-
slice computed tomographic analysis in 7 (14%) patients. However,
only 2 of these patients were symptomatic, and the clinical relevance
of this complication is undefined.
In conclusion, the results of our study suggest that symptomatic
and fatal PEs are uncommon complications in these patients. Un-
fractionated heparin and low-molecular-weight heparin seem to be
equally effective in reducing venous thromboembolic events also
in patients with metastatic disease. Large prospective studies are
warranted to confirm our results.
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down.1 Patients typically present with recurrent aspiration pneumo-
nia. Urgent repair of the fistula with tissue interposition is warranted,
although this can be challenging in the ventilated patient because of
the need for continued positive pressure ventilation and the paucity
of healthy, local tissue to fashion the repair. The present study is
a case report of a 65-year-old woman in whom a large TEF devel-
oped after bilobectomy and who was successfully treated with Allo-
Derm (LifeCell Corporation, Branchburg, NJ), a commercially
available biologic tissue. In this case, AlloDerm was used as a tissue
scaffold to reconstruct the defect in the trachea to serve and enhance
the integrity of the repair.2,3
Clinical Summary
A 65-year-old woman underwent right middle and lower lobectomy
for non–small cell lung carcinoma at an outside hospital. Her post-
operative course was marked by adult respiratory distress syndrome
and prolonged mechanical ventilation that required tracheostomy.
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